PT  - JOURNAL ARTICLE
AU  - Sheneé C. Martin
AU  - Sean M. Gay
AU  - Michael L. Armstrong
AU  - Nila M. Pazhayam
AU  - Nichole Reisdorph
AU  - Graham H. Diering
TI  - Tonic endocannabinoid signaling supports sleep through development in both sexes
AID  - 10.1101/2021.05.10.443432
DP  - 2021 Jan 01
TA  - bioRxiv
PG  - 2021.05.10.443432
4099  - http://biorxiv.org/content/early/2021/05/12/2021.05.10.443432.short
4100  - http://biorxiv.org/content/early/2021/05/12/2021.05.10.443432.full
AB  - Sleep is an essential behavior that supports brain function and cognition throughout life, in part by acting on neuronal synapses. The synaptic signaling pathways that mediate the restorative benefits of sleep are not fully understood, particularly in the context of development. Endocannabinoids (eCBs) including 2-arachidonyl glycerol (2-AG) and anandamide (AEA), are bioactive lipids that activate cannabinoid receptor, CB1, to regulate synaptic transmission and mediate cognitive functions and many behaviors, including sleep. We used targeted mass spectrometry to measure changes in forebrain synaptic eCBs during the sleep/wake cycle in developing and adult mice. We find that eCBs are downregulated in response to acute sleep deprivation in juvenile mice, while in young adults eCBs are upregulated during the sleep phase in a circadian manner. Next we manipulated the eCB system using selective pharmacology and measured the effects on sleep behavior in developing and adult mice of both sexes using a non-invasive piezoelectric home-cage recording apparatus. Enhancement of eCB signaling through inhibition of 2-AG or AEA degradation, increased dark phase sleep amount and bout length in developing and adult males, but not in females. Inhibition of CB1 by injection of the antagonist AM251 reduced sleep time and caused sleep fragmentation in developing and adult males and females. Our data suggest that males are more sensitive to the sleep promoting effects of enhanced eCBs but that tonic eCB signaling supports sleep behavior through multiple stages of development in both sexes. This work informs the further development of cannabinoid-based therapeutics for sleep disruption.Competing Interest StatementThe authors have declared no competing interest.